Accelerating access to psychotherapeutic medicines for patients with urgent and unmet mental health needs. MARCH 10th 2022 – VANCOUVER, BRITISH COLUMBIA, – Albert Labs International Corp. (the “Company”), a research and drug development company producing natural pharmaceutical-quality psilocybin medicine to treat cancer-related distress, is pleased to announce that its shares will commence trading…


Previous articleSmall Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
Next articleHPPD and Flashbacks: Everything You Need To Know – And What We Don’t Know, Too